I believe the reason for it having been in (and out) of trials for so long is that PTX200 has been trialed across three different cancer types, namely Breast, Ovarian and AML. Where all the data is leading, I'm not exactly sure but here are some slides from an August 2018 preso:-
Maybe @dalts66, @hottod, @BigDaniel or a LTH familiar with the history of this pathway that PTX is taking with its targeted therapies, could shed some light on the possible destination for this long journey of PTX200.... pleeeease?
PTX Price at posting:
12.8¢ Sentiment: Buy Disclosure: Held
